m K, Garcia Z, Poksay KS, Johnson DF, Lusis AJ, Innerarity TL (1990) Apolipoprotein B mRNA editing. Direct determination of the edited base and occurrence in non-apolipoprotein B-producing cell lines. J. Biol. Chem. 265:22446–22452.
Boyles JK, Notterpek LM, Anderson LJ (1990) Accumulation of apolipoproteins in the regenerating and remyelinating mammalian peripheral nerve. Identification of apolipoprotein D, apolipoprotein A-IV, apolipoprotein E, and apolipoprotein A-I. J. Biol. Chem. 265:17805–17815.
Boyles JK, Notterpek LM, Wardell MR, Rall SC Jr (1990) Identification, characterization, and tissue distribution of apolipoprotein D in the rat. J. Lipid Res. 31:2243–2256.
Chang DJ, Paik Y-K, Leren TP, Walker DW, Howlett GJ, Taylor JM (1990) Characterization of a human apolipoprotein E gene enhancer element and its associated protein factors. J. Biol. Chem. 265:9496–9504.
Chuck SL, Yao Z, Blackhart BD, McCarthy BJ, Lingappa VR (1990) New variation on the translocation of proteins during early biogenesis of apolipoprotein B. Nature 346:382–385.
Crook D, Weisgraber KH, Rall SC Jr, Mahley RW (1990) Isolation and characterization of several plasma apolipoproteins of common marmoset monkey. Arteriosclerosis 10:625–632.
Crook D, Weisgraber KH, Boyles JK, Mahley RW (1990) Isolation and characterization of plasma lipoproteins of common marmoset monkey. Comparison of effects of control and atherogenic diets. Arteriosclerosis 10:633–647.
Fox JEB, Austin CD, Boyles JK, Steffen PK (1990) Role of the membrane skeleton in preventing the shedding of procoagulant-rich microvesicles from the platelet plasma membrane. J. Cell Biol. 111:483–493.
Fox JEB, Reynolds CC, Austin CD (1990) The role of calpain in stimulus-response coupling: Evidence that calpain mediates agonist-induced expression of procoagulant activity in platelets. Blood 76:2510–2519.
Friedl W, Ludwig EH, Paulweber B, Sandhofer F, McCarthy BJ (1990) Hypervariability in a minisatellite 3« of the apolipoprotein B gene in patients with coronary heart disease compared with normal controls. J. Lipid Res. 31:659–665.
Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, Grundy SM, Friedl W, Davignon J, McCarthy BJ (1990) Familial defective apolipoprotein B100: A mutation of apolipoprotein B that causes hypercholesterolemia. J. Lipid Res. 31:1337–1349.
Innerarity TL (1990) Low density lipoprotein receptor-ligand interactions. In: Biotechnology of Dyslipoproteinemias: Applications in Diagnosis and Control (Lenfant C, Albertini A, Paoletti R, Catapano AL, eds) Raven Press, New York, pp 91–101.
Innerarity TL (1990) Mutations of apolipoprotein B that affect plasma cholesterol levels. In: Drugs Affecting Lipid Metabolism X (Gotto AM, Jr., Smith LC, eds) Elsevier Science, Amsterdam, pp 141–144.
Innerarity TL (1990) Familial hypobetalipoproteinemia and familial defective apolipoprotein B100: Genetic disorders associated with apolipoprotein B. Curr. Opin. Lipidol. 1:104–109.
Innerarity TL, Bostrsm K (1990) Mutations and variants of apolipoprotein B that affect plasma cholesterol levels. Adv. Exp. Med. Biol. 285:25–31.
Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL (1990) Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J. Biol. Chem. 265:10771–10779.
Kunitake ST, Young SG, Chen GC, Pullinger CR, Zhu S, Pease RJ, Scott J, Hass P, Schilling J, Kane JP (1990) Conformation of apolipoprotein B-100 in the low density lipoproteins of Tangier disease. Identification of localized conformational response to triglyceride content.J. Biol. Chem. 265:20739–20746.
Levy-Wilson B (1990) DNaseI hypersensitive sites at the 3« end of the human apolipoprotein B gene. Biochem. Biophys. Res. Commun. 171:162–168.
Ludwig EH, McCarthy BJ (1990) Haplotype analysis of the human apolipoprotein B mutation associated with familial defective apolipoprotein B100. Am. J. Hum. Genet. 47:712–720.
Mahley RW (1990) Biochemistry and physiology of lipid and lipoprotein metabolism. In: Principles and Practice of Endocrinology and Metabolism (Becker KL, eds) J. B. Lippincott, Philadelphia, pp 1219–1229, 1271.
Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH, Taylor JM (1990) Apolipoprotein E: Genetic variants provide insights into its structure and function. Curr. Opin. Lipidol. 1:87–95.
Mahley RW (1990) Type III hyperlipoproteinemia: Dominant versus recessive expression of this lipoprotein disorder. In: Drugs Affecting Lipid Metabolism X (Gotto AM, Jr., Smith LC, eds) Elsevier Science, Amsterdam, pp 29–34.
Parise LV, Criss AB, Nannizzi L, Wardell MR (1990) Glycoprotein IIIa is
Pitas RE (1990) Expression of the acetyl low density lipoprotein receptor by rabbit fibroblasts and smooth muscle cells. Up-regulation by phorbol esters. J. Biol. Chem. 265:12722–12727.
Rall SC Jr, Innerarity TL, Weisgraber KH, Wardell MR, Mahley RW (1990) The type of mutation in apolipoprotein E determines whether type III hyperlipoproteinemia is expressed as a dominant or recessive trait. In: Atherosclerosis and Cardiovascular Disease. 7th International Meeting (Descovich GC, Gaddi A, Magri GL, Lenzi S, eds) Kluwer Academic Publishers, Dordrecht, The Netherlands, pp 81–88.
Simonet WS, Bucay N, Lauer SJ, Wirak DO, Stevens ME, Weisgraber KH, Pitas RE, Taylor JM (1990) In the absence of a downstream element, the apolipoprotein E gene is expressed at high levels in kidneys of transgenic mice. J. Biol. Chem. 265:10809–10812.
Molecular Biology of Atherosclerosis (Attie AD, eds) Elsevier Science, New York, pp 3–9.
Simonet WS, Bucay N, Lauer SJ, Pitas RE, Weisgraber KH, Taylor JM (1990) Downstream regulatory elements stimulate expression of the human apolipoprotein E gene in the liver and suppress expression in the kidney of transgenic mice. Trans. Assoc. Am. Physicians 103:119–128.
Taylor JM, Chang DJ, Leren TP, Walker D, Lauer SJ (1990) Regulatory elements of the apolipoprotein E gene. Atheroscler. Rev. 20:47–53.
Taylor JM, Paik Y-K, Chang DJ, Simonet WS, Bucay N, Leren T, Walker D, Lauer SJ (1990) Regulatory elements of the apolipoprotein E gene and its expression in transgenic mice. In: Drugs Affecting Lipid Metabolism X (Gotto AM, Jr., Smith LC, eds) Elsevier Science, Amsterdam, pp 165–167.
Wardell MR, Rall SC Jr, Brennan SO, Nye ER, George PM, Janus ED, Weisgraber KH (1990) Apolipoprotein E2-Dunedin (228 Arg!’Cys): An apolipoprotein E2 variant with normal receptor-binding activity. J. Lipid Res. 31:535–543.
Weisgraber KH (1990) Apolipoprotein E distribution among human plasma lipoproteins: Role of the cysteine-arginine interchange at residue 112. J. Lipid Res. 31:1503–1511.
Weisgraber KH, Innerarity TL, Rall SC Jr, Mahley RW (1990) Atherogenic lipoproteins resulting from genetic defects of apolipoproteins B and E. Ann. N.Y. Acad. Sci. 598:37–48.
Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL, Brown MS (1990) Apolipoprotein C-I modulates the interaction of apolipoprotein E with b-migrating very low density lipoproteins (b-VLDL) and inhibits binding of b-VLDL to low density lipoprotein receptor-related protein. J. Biol. Chem. 265:22453–22459.
Young SG, Hubl ST, Smith RS, Snyder SM, Terdiman JF (1990) Familial hypobetalipoproteinemia caused by a mutation in the apolipoprotein B gene that results in a truncated species of apolipoprotein B (B-31). A unique mutation that helps to define the portion of the apolipoprotein B molecule required for the formation of buoyant, triglyceride-rich lipoproteins. J. Clin. Invest. 85:933–942.
Young SG (1990) Recent progress in understanding apolipoprotein B. Circulation 82:1574–1594.
TOP
